Kiora Pharmaceuticals (KPRX)
(Delayed Data from NSDQ)
$2.36 USD
-0.03 (-1.26%)
Updated Aug 8, 2025 04:00 PM ET
After-Market: $2.40 +0.04 (1.69%) 7:58 PM ET
3-Hold of 5 3
A Value A Growth B Momentum A VGM
Fundamental Charts
About Cash from Investing (TTM)
The company's trailing twelve month (TTM) Cash from Investing is the sum of the company's past 12 months cash position resulting from any gains or losses from investments in the financial markets, operating activities, and changes resulting from amounts spent on investments in capital assets such as plant and equipment. When evaluating the Cash from Investing value, it is important to consider each of the various activities which contribute to the overall change in cash position. A company can have a negative cash flow from investing and have a positive cash from Cash from operations or financing.
KPRX 2.36 -0.03(-1.26%)
Will KPRX be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for KPRX based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for KPRX
Kiora Pharmaceuticals (KPRX) Upgraded to Strong Buy: Here's What You Should Know
KPRX: What are Zacks experts saying now?
Zacks Private Portfolio Services
Other News for KPRX
Kiora Pharmaceuticals Reports Second Quarter 2025 Results; Company Advances Pipeline with Two ...
Kiora Pharmaceuticals GAAP EPS of -$0.54
Kiora Pharmaceuticals to Showcase Its Retinal Disease Therapeutic Pipeline at The H.C. ...
KPRX Receives Positive Outlook Following New U.S. Patent | KPRX Stock News
Kiora Pharmaceuticals granted new patent for KIO-104, says H.C. Wainwright